Autolus Therapeutics plc American Depositary Share (AUTL)

Autolus Therapeutics reported Q2 2025 net product sales of $20.9 million for AUCATZYL®, received marketing authorization in the UK and EU, and presented long-term data from the FELIX trial demonstrating potential for long-term remission in relapsed/refractory B-ALL.

4 analysts have expressed a variety of opinions on Autolus Therapeutics (NASDAQ:AUTL) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.0, a high estimate of $10.00, and a low estimate of $8.00. This current average has increased by 9.09% from the previous average price target of $8.25. Decoding Analyst Ratings: A Detailed Look The standing of Autolus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gil Blum Truist Securities Raises Buy $10.00 $9.00 Gil Blum Needham Maintains Buy $9.00 $9.00 Gil Blum Needham Raises Buy $9.00 $8.00 Gil Blum Needham Raises Buy $8.00 $7.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ...Full story available on Benzinga.com

Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

The biopharmaceutical company announced the pricing of a secondary stock offering.

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.